Literature DB >> 23561591

Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States cohort.

Yuan-Yuan Zhang1, Chunfu Qiu, Pamela J Davis, Mehul Jhaveri, Eric N Prystowsky, Peter Kowey, William S Weintraub.   

Abstract

The progression of atrial fibrillation (AF) to a more sustained form is associated with increased symptoms and morbidity. The aims of the REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States (US) cohort study were to identify the risk factors of AF progression and the effects of management approaches. RecordAF is the first worldwide, 1-year observational study of the treatment of community-based patients with recent-onset AF. We assessed AF progression at 12 months in the US cohort. AF progression was defined as a change of AF to a more sustained form (either paroxysmal becoming persistent or permanent, or persistent becoming permanent). The US cohort included 955 patients, with mean age of 68.9 years; 56.8% were men and 88.8% were white. At entry, 59.6% of patients were selected for rate-control and 40.4% for rhythm-control therapy. At 12 months, the management strategy was unchanged for 68.2% of the patients in the rate- and 77.7% of the patients in the rhythm-control groups. Overall, AF progression had occurred in 18.6% of patients at 12 months. The progression rate was significantly greater in the rate-control (27.6%) than in the rhythm-control (5.8%) group (p <0.001). Progression to permanent AF occurred in 16.4% of patients. In addition to a rate-control strategy, older age, AF rhythm at entry, persistent AF at baseline, and a history of stroke or transient ischemic attack independently predicted AF progression. Rate control was associated with AF progression, with a propensity score adjusted odds ratio of 2.67 (p <0.001). In conclusion, rate control was the preferred treatment of recent-onset AF in the US but was associated with more AF progression than rhythm control.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23561591     DOI: 10.1016/j.amjcard.2013.02.056

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry.

Authors:  Yoshimori An; Masahiro Esato; Mitsuru Ishii; Moritake Iguchi; Nobutoyo Masunaga; Hikari Tsuji; Hiromichi Wada; Koji Hasegawa; Hisashi Ogawa; Mitsuru Abe; Gregory Y H Lip; Masaharu Akao
Journal:  Heart Vessels       Date:  2018-05-24       Impact factor: 2.037

2.  Dietary Fat Intake Is Differentially Associated with Risk of Paroxysmal Compared with Sustained Atrial Fibrillation in Women.

Authors:  Stephanie E Chiuve; Roopinder K Sandhu; M Vinayaga Moorthy; Robert J Glynn; Christine M Albert
Journal:  J Nutr       Date:  2015-07-15       Impact factor: 4.798

Review 3.  Racial, ethnic, and sex disparities in atrial fibrillation management: rate and rhythm control.

Authors:  Sofia E Gomez; Muhammad Fazal; Julio C Nunes; Shayena Shah; Alexander C Perino; Sanjiv M Narayan; Kamala P Tamirisa; Janet K Han; Fatima Rodriguez; Tina Baykaner
Journal:  J Interv Card Electrophysiol       Date:  2022-10-13       Impact factor: 1.759

4.  Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation.

Authors:  Qingsong Chen; Yunlin Chen; Fang Qin; Huaan Du; Chunxia Gan; Bei Zhou; Na Wang; Mingyang Xiao; Zhenhong Ou; Wei Zhao; Ben Cui; Zengzhang Liu; Yuehui Yin
Journal:  Front Cardiovasc Med       Date:  2022-05-30

5.  Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.

Authors:  Gerald V Naccarelli; Riccardo Cappato; Stefan H Hohnloser; Francis E Marchlinski; David J Wilber; Jim Xiang; Changsheng Ma; Susanne Hess; David Wyn Davies; Larry E Fields; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2014-07-09       Impact factor: 1.900

6.  Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis.

Authors:  Dimitris Tsiachris; Ioannis Doundoulakis; Eirini Pagkalidou; Athanasios Kordalis; Spyridon Deftereos; Konstantinos A Gatzoulis; Konstantinos Tsioufis; Christodoulos Stefanadis
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-05       Impact factor: 3.727

7.  Efficacy and speed of conversion of recent onset atrial fibrillation using oral propafenone versus parenteral amiodarone: A randomized controlled comparative study.

Authors:  Hesham S Taha; Ghada Youssef; Ramy M Omar; Ahmed M Kamal El Din; Ahmed A Shams El Din; Marwa S Meshaal
Journal:  Indian Heart J       Date:  2022-04-19

8.  Heart rate is associated with progression of atrial fibrillation, independent of rhythm.

Authors:  Fredrik Holmqvist; Sunghee Kim; Benjamin A Steinberg; James A Reiffel; Kenneth W Mahaffey; Bernard J Gersh; Gregg C Fonarow; Gerald V Naccarelli; Paul Chang; James V Freeman; Peter R Kowey; Laine Thomas; Eric D Peterson; Jonathan P Piccini
Journal:  Heart       Date:  2015-03-02       Impact factor: 5.994

9.  Incidence and Predictors of Atrial Fibrillation Progression.

Authors:  Steffen Blum; Stefanie Aeschbacher; Pascal Meyre; Leon Zwimpfer; Tobias Reichlin; Jürg H Beer; Peter Ammann; Angelo Auricchio; Richard Kobza; Paul Erne; Giorgio Moschovitis; Marcello Di Valentino; Dipen Shah; Jürg Schläpfer; Selina Henz; Christine Meyer-Zürn; Laurent Roten; Matthias Schwenkglenks; Christian Sticherling; Michael Kühne; Stefan Osswald; David Conen
Journal:  J Am Heart Assoc       Date:  2019-10-08       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.